Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti

First Multiple Myeloma Patient Could Be Infused In Six Weeks

Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage. 

Red balloon mid air amongst wooden square cubes
A phased launch will allow for careful certification of treatment centers • Source: Alamy

Janssen Pharmaceutical Cos. and Legend Biotech Corp. plan a phased launch of their newly approved autologous chimeric antigen receptor T-cell (CAR-T) multiple myeloma therapy Carvykti (ciltacabtagene autoleucel), which targets B-cell maturation antigen (BCMA) on myeloma cells, to make sure treatments centers are ready to properly administer the complex product.

Johnson & Johnson’s Janssen subsidiary and Legend will launch Carvykti at a list price of $465,000 for the one-time...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.

Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach

 
• By 

A deal last year with Sanofi relieved Novavax of commercial costs for the COVID-19 vaccine Nuvaxovid, allowing the company to focus on R&D and finding partners for its other vaccines.

Pharma Gets A Compatriot At CDER With Tidmarsh Appointment To Top Spot

 

Drug manufacturers may find comfort in the appointment of former biotech CEO and entrepreneur George Tidmarsh to lead the FDA’s Center for Drug Evaluation and Research.